ImmunoGen Investor Relations Material
Latest events
Q3 2023
ImmunoGen
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from ImmunoGen Inc
Access all reports
ImmunoGen, Inc., is a clinical-stage biotechnology company. The company develops antibody-drug conjugate therapies to treat cancer. Its ADC product candidates include Binimetinib, an ADC designed to treat non-small cell lung cancer, colorectal cancer, and pancreatic cancer; Daratumumab, an ADC designed to treat multiple myeloma; and SAR302503, an ADC that combines trastuzumab with an anthracycline. The company's ADC product candidates are currently in various stages of clinical development. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Latest articles
Master of Tickets: Breaking Down Live Nation Entertainment
Since merging in 2010, Ticketmaster and Live Nation have built an expansive ecosystem that dominates global live entertainment.
6 Dec 2024
Peter Beck: The Innovator at Rocket Lab
Peter Beck, born and raised in New Zealand, is one of the key individuals in the aerospace industry as the founder and CEO of Rocket Lab.
6 Dec 2024
Prada: The Story of an Icon
Prada's journey from a small Milan boutique to a global luxury empire, led by Miuccia's innovation and creativity.
5 Dec 2024
Ticker symbol
IMGN
Country
🇺🇸 United States